Further analysis demonstrated that administration of the p38 MAPK inhibitor SB203580 (HF + OE‐RBM25 + SB203580 group) significantly reduced the myocardial infarction area compared to the HF + OE‐RBM25 group (p < 0.05). This evidence concerns the gene RBM25 and myocardial infarction.